$TSEM

Fri: Weak defense stocks weigh on indices

Friday on the Tel Aviv Stock Exchange, major indices declined. Tel Aviv 35 fell 0.33% to 4,202.63 and Tel Aviv 125 fell 0.31% to 4,074.63. Defense and renewable energy sector indices dropped, while chemicals rubber and plastics rose. FX rates weakened versus the dollar and euro. Bank Hapoalim rose 0.31%, Tower Semiconductor fell 4.35%, Teva fell 2.28%.

Original reporting
Published Aug 16, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 16, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fri: Weak defense stocks weigh on indices — source image
Decision brief

The 30-second read

$TSEMNeutralLow
01

Why it matters

The only explicit fundamental event is Nofar Energy’s announced acquisition of HighLight for NIS 200 million; other listed moves are presented without catalysts.

02

Market read

Traders get a same-day read on TASE risk appetite, with defense and renewables under pressure and one deal-driven single-name catalyst.

03

What to watch

Defense and renewable weakness may reflect macro or hedging flows rather than company fundamentals; without attribution, single-name moves may be non-informational.

Relevance 4/10Novelty 3/10Timing: Friday session market wrap, mid-day timestamp (13:30 UTC)

Background

This is a Tel Aviv market wrap describing index performance, sector moves, FX moves, and a list of notable single-stock gainers and losers.

Company-level read

Ticker impact

$TSEMNeutralLow confidence
Context

Tower Semiconductor dropped 4.35% on Friday, listed as a notable decliner in the article.

Expected impact

Short-term volatility possible, but directionally unconfirmed by fundamentals here.

Evidence & confidence

The article lacks a catalyst; it is a market wrap with price moves only.

$TEVANeutralLow confidence
Context

Teva fell 2.28% on Friday, included in the article’s notable decliners list.

Expected impact

No high-conviction trade signal from this article alone.

Evidence & confidence

Only the daily move is provided; no earnings, trial, or guidance update appears.

$NICENeutralLow confidence
Context

Nice rose 6.48% on Friday, called out as a notable advancer in the article.

Expected impact

Potential momentum, but catalyst risk remains high without further detail.

Evidence & confidence

The article reports the move magnitude without explaining what drove it.

$GILTNeutralLow confidence
Context

Gilat Satellite Systems fell 4.43% on Friday, listed among notable decliners.

Expected impact

Limited actionable signal without a stated catalyst.

Evidence & confidence

No event, filing, or guidance change is described for Gilat.

Market effects

Defense and renewable energy sector indices fell 1.62% and 1.49%, suggesting risk-off rotation within TASE sectors.

Broader Tel Aviv index weakness alongside shekel depreciation (USD -0.97%, EUR -0.83%) may pressure risk assets.

Limited direct global linkage; mainly a regional tape and sector rotation snapshot.

Counterpoint

The article’s biggest single-company catalyst is an acquisition, but the stock drop could be an overreaction that reverses if deal terms are later clarified.

Key entities

  • Tel Aviv 35 Index

    Fell 0.33% to 4,202.63 points on Friday.

  • Tel Aviv Defense Index

    Dropped 1.62% on Friday.

  • Nofar Energy

    Fell 5.42% after announcing acquisition of HighLight for NIS 200 million.

  • HighLight

    Solar energy and storage company being acquired by Nofar Energy.

Related articles

$GILTHighAI 9/10

Gilat Satellite Networks Targets Defense, In-Flight Growth With Comtech Deal

Gilat Satellite Networks (GILT) said it is expanding in defense and in-flight connectivity, citing its role as equipment provider for SES’s O3b mPOWER and OneWeb gateway amplifiers. CEO Adi Sfadia discussed a $43 million Sidewinder order. Gilat reported Q2 revenue of $122M (+17%) and EBITDA $15.4M (+31%), and expects 2024 revenue of $500M-$520M. It agreed to acquire Comtech for $157M cash.

$NICEHighAI 9/10

NICE (NICE) Q2 2026 Earnings Call Transcript

NICE Ltd. reported Q2 2026 revenue of $782 million, up 8% year over year, and cloud revenue of $609 million, up 12.6%. Non-GAAP EPS was $2.70. Management cited CX AI and self-service ARR of $362 million (+52%), operating margin of 25.3%, and free cash flow of $93 million. Full-year 2026 revenue guidance is $3.170B to $3.190B.

$TSEMHighAI 9/10

Tower Semiconductor (TSEM) Q2 2026 Earnings Call Transcript

Tower Semiconductor (TSEM) reported Q2 2026 revenue of $460 million, up 11% sequentially and 24% year over year. Management guided Q3 revenue to $520 million (midpoint) and raised its 2028 model to $3.6 billion revenue. Non-GAAP diluted EPS was $0.79. CapEx is $920 million and silicon photonics capacity targets a $1 billion run rate by Q4 2026.

$TEVAMed

Moody’s upgrades Teva rating to investment grade on debt cuts

Moody’s Ratings upgraded Teva Pharmaceutical Industries (NYSE:TEVA) to investment grade, raising its issuer rating to Baa3 from Ba1 and changing the outlook to stable from positive. Moody’s cited branded sales growth, pipeline expansion, and deleveraging. It expects gross debt/EBITDA to fall below 3.75x, and forecasts about $2.0B free cash flow over 12 months.

$TEVAMed

Teva Pharmaceutical Industries Ltd: Moody's Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Teva Pharmaceutical Industries (NYSE: TEVA) said Moody’s upgraded its corporate credit rating to Baa3 from Ba1 with a stable outlook. Moody’s cited execution of Teva’s Pivot to Growth strategy, including growth products, pipeline expansion, and continued debt reduction supported by earnings growth, plus improving margins and free cash flow. Teva expects further debt reduction over 12 to 18 months.

$TEVAMedAI 8/10

Teva (TEVA) Q2 2026 Earnings Call Transcript

Teva (TEVA) reported Q2 2026 revenue of $4.1B, down 1% year over year due to lower U.S. generic sales. Innovative brands rose, including AUSTEDO $696M (+40%), AJOVY $244M (+56%), and UZEDY $77M (+43%). Non-GAAP EPS was $0.02 and free cash flow was $622M (+31%). 2026 revenue guidance was raised to $16.5B-$16.85B; net debt was $12.9B (2.8x).

Fri: Weak defense stocks weigh on indices — alphai